Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, CANADA, HONG KONG, BELARUS, RUSSIA OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLISHING OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW. SEE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
NextCell Pharma AB (publ) ("NextCell" or the "Company") has today published a supplement (the "Supplement") to the EU Growth prospectus, which was approved and registered by the Swedish Financial Supervisory Authority and published on 30 May 2024 (the "Prospectus"). The Supplement has been prepared due to the fact that the Company on 4 June 2024 announced through a press release that the Company had agreed to a so-called top guarantee of a total of approximately SEK 8.0 million in the ongoing rights issue of units in the Company (the "Rights Issue").
The Supplement, which today on 10 June 2024 has been approved by the Swedish Financial Supervisory Authority, forms part of, and must be read together with, the Prospectus. The Prospectus and the Supplement (together the "Prospectuses") are available on the Company's website, www.nextcellpharma.com, and on Redeye's website, www.redeye.se, and will be available on the Swedish Financial Supervisory Authority's website, www.fi.se.
Those who have already subscribed or applied for subscription of units in the Rights Issue are entitled to withdraw their subscription or application within two business days from the publication of the Supplement, i.e. until and including 12 June 2024. Any subscription or application that is not withdrawn within the prescribed time will remain binding and those who wish to remain with their subscription or application do not need to take any further action. Further instructions on how to withdraw a subscription or an application are to be found in the Supplement.
For full terms and conditions and other information on the Rights Issue, please refer to the Prospectuses.
Advisors
Redeye AB is financial advisor to NextCell in connection with the Rights Issue. Törngren Magnell & Partners Advokatfirma KB is legal advisor to the NextCell in connection with the Rights Issue.